Cerevance
PrivateLast Round
Series C
May 12, 2026
Total Funding Raised
$209.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Cerevance operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series C round in May 2026.
Cerevance is a biotechnology company focused on developing innovative therapeutics to create new treatments for central nervous system diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cerevance Comparables
Compare Cerevance with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QurAlis | 78% | |
| Neumora | 78% | |
| ProMIS Neurosciences Inc. | 77% |
For institutional investors. Book with your work email.
Cerevance Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 12, 2026 | ||||
| Series B Extension | Apr 25, 2024 | ||||
| Series B Extension | Feb 13, 2023 | ||||
| Series B Extension | Jul 21, 2020 | ||||
| Series B | Apr 14, 2020 | ||||
VC Round | Feb 21, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cerevance Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Series B Extension |
| Dolby Family Ventures | Series B Extension |
| SV Health Investors | Series C, Series A, Series B, Series B Extension, VC Round |
| GV | Series C, Series B Extension, Series B |
| Lightstone Ventures | Series C, Series B Extension, Series B, Series A |
| Bioluminescence Ventures | Series B Extension |
| Bellco Capital | Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 22, 2026
Monthly visitors increased 36% MoM.
- May 12, 2026
$20M round with participation from GV and UPMC Enterprises.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 7, 2026
On Oct 7th '26, Cerevance is developing solengepras as a once-daily add-on treatment for Parkinson’s patients with motor fluctuations despite levodopa and other drugs; its late-stage trial meets its main goal at the higher dose.
- hiresOct 5, 2026
Cerevance appoints Karl Kieburtz, M.D., M.P.H., as chief medical officer in Massachusetts on Oct 5th '26, expanding the leadership team as it advances solengepras through Phase 3 development for Parkinson's disease.
For institutional investors. Book with your work email.
Cerevance Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cerevance's valuation, stock price, and market status.
Is Cerevance a public or private company?
Cerevance is a private company.
What is the current stock price of Cerevance?
Cerevance is a private company, so its shares have no public market price. Caplight tracks Cerevance's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cerevance worth (valuation)?
Valuation information for Cerevance is not publicly available.
Can I buy Cerevance stock?
Cerevance shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cerevance's last funding round?
Cerevance's most recent funding round was Series C on May 12, 2026.
Who are the main investors in Cerevance?
Key investors in Cerevance include Agent Capital, Dolby Family Ventures, GV, Lightstone Ventures, Bioluminescence Ventures.
Will Cerevance IPO soon?
No public IPO plans have been announced for Cerevance.
How can I track Cerevance secondary market activity?
Caplight tracks bids, offers, and trades in Cerevance's shares on secondary markets.